Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -8.6M | 2.1% |
| Cost of Revenue | 8.6M | 15.6% |
| Operating expense | 27M | 17.9% |
| Net Income | -25M | 21.9% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 107M | 20% |
| Total Liabilities | 34M | 9.5% |
| Total Equity | 74M | 24% |
| Shares Outstanding | 26M | 0.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -27M | 2.7% |
| Cash from investing | 14M | 41.3% |
| Cash from financing | 660,000 | 98% |
EPS
Financial Highlights for Inovio Pharmaceuticals in Q3 '24
Gross Profit stood at -8.6M, marking a 2.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 8.6M, a -15.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 27M, showing a -17.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -25M, showing a 21.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Inovio Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
